Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03143608 · ClinicalTrials.gov registry record
GERD Treatment With Transoral Incisionless Fundoplication (TIF) Following Hiatal Hernia Surgery
A clinical trial of Gastroesophageal Reflux, sponsored by Peter G Mavrelis.
- Completed
- Registry status
- 99
- Enrollment target
- 2
- Study locations
NCT03143608: Completed study of Gastroesophageal Reflux, sponsored by Peter G Mavrelis.
NCT03143608 is a study of Gastroesophageal Reflux that has completed, run by Peter G Mavrelis. The registered enrollment target is 99 participants, below the 2,883-participant average among 33 other Gastroesophageal Reflux trials with a reported enrollment target (97% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03143608, a study of Gastroesophageal Reflux, has completed, sponsored by Peter G Mavrelis.
- COMPLETED
- Registry status
- 99 participants
- Enrollment target
- 2
- Study locations
Study Summary
The investigators prospectively studied ninety nine GERD patients following laparoscopic hiatal surgery combined with transoral incisionless fundoplication at two community hospitals. General surgeons and gastroenterologists participated in the study. GERD questions were recorded before and at six and twelve months.
Primary Outcome
GERD health related quality of life questionnaire
Conditions Studied
Interventions
- DEVICE Esophyx
Study Locations (2)
Indiana
- Methodist Hospital - Merrillville
Wisconsin
- Affinity Health System - Appleton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 99 participants |
| Start Date | 2014-05-01 |
| Est. Completion | 2016-12-31 |
What the finished NCT03143608 record still lists
NCT03143608 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 99 participants, a relatively small participant target, below the 2,883-participant average among 33 other Gastroesophageal Reflux trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Gastroesophageal Reflux appearing as the primary indexed condition, and to 1 intervention - of which Esophyx is the first listed.
NCT03143608 reports a single indexed study location in Indiana, Wisconsin.
Frequently Asked Questions
What is clinical trial NCT03143608 about?
NCT03143608 is a clinical study titled "GERD Treatment With Transoral Incisionless Fundoplication (TIF) Following Hiatal Hernia Surgery". The investigators prospectively studied ninety nine GERD patients following laparoscopic hiatal surgery combined with transoral incisionless fundoplication at two community hospitals. General surgeons and gastroenterologists participated in the study. GERD questions were recorded before and at six a...
What is the current status of trial NCT03143608?
This trial is currently completed. The enrollment target is 99 participants. The study started on 2014-05-01. Estimated completion is 2016-12-31.
What conditions does trial NCT03143608 study?
This clinical trial studies the following conditions: Gastroesophageal Reflux.
What interventions are being tested in trial NCT03143608?
The interventions under investigation include: Esophyx (DEVICE).
Who is sponsoring clinical trial NCT03143608?
This trial is sponsored by Peter G Mavrelis, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03143608 being conducted?
This trial has 2 study locations across Indiana, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gastroesophageal Reflux
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03143608's enrollment target sits among peer trials
99 16th of 33 higher than 18 of 33 other Gastroesophageal Reflux trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Gastroesophageal Reflux trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Breath Testing for Small Intestinal Bacterial Overgrowth
RECRUITING · NA
-
Transpyloric Versus Gastric Feeding in Bronchopulmonary Dysplasia
RECRUITING · NA
-
Compassionate Use of Domperidone for Refractory Gastroparesis
RECRUITING · NA
-
Barrett's Esophagus Related Neoplasia (BERN) Project
RECRUITING
-
External UES Band (Shaker Pressure Band) and GERD
RECRUITING · NA
-
Multi-Site Detection of Barrett's Esophagus in Patients Without Chronic GERD Symptoms
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03965234 · 99 participants · Phase 1
Pulmonary Suffusion in Controlling Minimal Residual Disease in Patients With Sarcoma or Colorectal Metastases
- NCT04022616 · 99 participants
Myeloid-Derived Suppressor Cell Function in Breast Cancer Patients
- NCT04042844 · 99 participants · Phase 2
A Single Dose of BRTX 100 for Patients With Chronic Lumbar Disc Disease (cLDD)
- NCT04143724 · 99 participants · Phase 2
Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-Thalassemia
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI